Skip to site menu Skip to page content

Daily Newsletter

01 November 2023

Daily Newsletter

01 November 2023

Weill Cornell to expand clinical presence in Midtown Manhattan

This expansion involves adding 100,000ft² to the existing space, which had previously been used for administrative purposes.

October 31 2023

US-based Weill Cornell Medicine is set to expand its presence in Midtown East Manhattan in New York by 2025.

This expansion involves adding 100,000ft² to its existing space, which had previously been used for administrative purposes.

Weill Cornell Medicine Stephen and Suzanne Weiss dean of Dr Robert A. Harrington said: “This expansion project is very exciting for our institution as we seek to broaden our footprint in New York City.

“This new space at 575 Lexington will allow us to offer the best care possible to more patients citywide and will add to our growing enterprise focused on excellence in clinical care, medical research and education.”

The newly acquired space will undergo renovations to offer advanced clinical care services, located near Grand Central Terminal and three major subway lines.

The organisation had initially leased 200,000ft² for administrative offices serving its institutional staff.

Under the new agreement, the usage of the space is being restructured, expanding it to include a new separate lobby entrance, occupying a total of nine floors.

This expansion is said to be part of Weill Cornell Medicine's efforts to enhance access to medical care in New York City.

The move follows the recent expansions in Long Island City and Southampton.

Construction is scheduled to start in the second quarter of 2024, with clinical practices expected to open in the fourth quarter of 2025.

Weill Cornell Medicine physician organisation president and CEO Dr Robert Min said: “The new space at 575 Lexington will be a convenient destination for patients living and working in Midtown Manhattan to receive exemplary care from Weill Cornell Medicine physicians and care providers.

“Reaching and providing care to the greatest number of patients in New York City is our top priority.”

Is the healthcare industry ready to fully embrace the benefits of digitalization and AI?

The healthcare, pharma, and medical devices industries are often risk-averse compared to other sectors when adopting new technologies. However, mainly due to COVID-19, these sectors have witnessed an acceleration in digital transformation. AI can revolutionize the drug discovery process and significantly reduce the time and cost to get a drug to market, particularly in areas of unmet need. There is also huge potential for AI in medical diagnostics. However, using healthcare data for AI development raises data privacy concerns, thereby limiting its adoption.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close